Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Organon Is Ready To Launch And Makes The Case To Investors

Established Products Will Account For The Majority Of Revenues

Executive Summary

Merck & Co. plans to spin off Organon in June as a diversified health care company focused on women's health, biosimilars and established products.

You may also be interested in...



Viatris Sets The Bar Low So There Will Eventually Be A Chance To Grow

Viatris' 2021 financial guidance was below investor expectations, suggesting a challenging road ahead for the newly formed company.

Merck To Spin Out A New Company, Following Industry's Downsizing Trend

Merck will spinout its mature franchises, including women's health products, into a new company that will have about $6bn-$6.5bn in 2021 revenues and be poised for modest growth.

Pfizer DMD Gene Therapy Phase III Trial Stalled In US After FDA Questions On Potency Assays

Pfizer disclosed that a Phase III trial for the gene therapy has been unable to start in the US because of questions from the FDA, even while enrollment in 15 sites outside the US is under way.

Topics

Related Companies

UsernamePublicRestriction

Register

SC144286

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel